<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Gastroenterol Hepatol</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Gastroenterol Hepatol</journal-id>
<journal-id journal-id-type="publisher-id">TGH</journal-id>
<journal-title-group>
<journal-title>Translational Gastroenterology and Hepatology</journal-title>
</journal-title-group>
<issn pub-type="epub">2415-1289</issn>
<publisher>
<publisher-name>AME Publishing Company</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32258527</article-id>
<article-id pub-id-type="pmc">7063531</article-id>
<article-id pub-id-type="publisher-id">tgh-05-2019.10.10</article-id>
<article-id pub-id-type="doi">10.21037/tgh.2019.10.10</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genome editing technologies to treat rare liver diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Trevisan</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="author-notes" rid="afn2">
<sup>#</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Masi</surname>
<given-names>Giulia</given-names>
</name>
<xref ref-type="author-notes" rid="afn2">
<sup>#</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Palù</surname>
<given-names>Giorgio</given-names>
</name>
</contrib>
<aff id="aff1">Department of Molecular Medicine, <institution>University of Padova</institution>, <addr-line>Padova</addr-line>, <country>Italy</country></aff>
</contrib-group>
<author-notes>
<fn id="afn1">
<p><italic>Contributions:</italic> (I) Conception and design: G Masi, M Trevisan; (II) Administrative support: None; (III) Provision of study material or patients: None; (IV) Collection and assembly of data: G Masi, M Trevisan; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p>
</fn>
<fn fn-type="equal" id="afn2">
<label>#</label>
<p>These authors contributed equally to this work.</p>
</fn>
<corresp id="cor1"><italic>Correspondence to:</italic> Giorgio Palù. Department of Molecular Medicine, University of Padova, via Gabelli 63, 35121 Padua, Italy. Email: <email xlink:href="giorgio.palu@unipd.it">giorgio.palu@unipd.it</email>.</corresp>
<fn fn-type="COI-statement">
<p><italic>Conflicts of Interest</italic>: The authors have no conflicts of interest to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>5</volume>
<elocation-id>23</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>2020 Translational Gastroenterology and Hepatology. All rights reserved.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Translational Gastroenterology and Hepatology.</copyright-holder>
</permissions>
<abstract>
<p>Liver has a central role in protein and lipid metabolism, and diseases involving hepatocytes have often repercussions on multiple organs and systems. Hepatic disorders are frequently characterized by production of defective or non-functional proteins, and traditional gene therapy approaches have been attempted for years to restore adequate protein levels through delivery of transgenes. Recently, many different genome editing platforms have been developed aimed at correcting at DNA level the defects underlying the diseases. In this Review we discuss the latest applications of these tools applied to develop therapeutic strategies for rare liver disorders, in particular updating the literature with the most recent strategies relying on base editors technology.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>Rare liver diseases</kwd>
<kwd>hepatocytes</kwd>
<kwd>gene therapy</kwd>
<kwd>genome editing</kwd>
<kwd>base editors</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>